Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CFO Charles N. York II acquired 25,959 shares of the stock in a transaction on Tuesday, December 5th. The shares were bought at an average price of $4.48 per share, with a total value of $116,296.32. Following the purchase, the chief financial officer now directly owns 10,828 shares of the company’s stock, valued at approximately $48,509.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Aeglea Bio Therapeutics Inc (NASDAQ AGLE) traded up $0.14 during trading hours on Thursday, reaching $4.88. The company’s stock had a trading volume of 68,600 shares, compared to its average volume of 65,913. Aeglea Bio Therapeutics Inc has a 1-year low of $2.81 and a 1-year high of $8.14.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.07. The business had revenue of $1.26 million during the quarter. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. equities research analysts forecast that Aeglea Bio Therapeutics Inc will post -1.97 EPS for the current fiscal year.
Separately, Zacks Investment Research upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Friday, November 10th.
A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Aeglea Bio Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after buying an additional 12,966 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Aeglea Bio Therapeutics during the first quarter valued at $157,000. Renaissance Technologies LLC purchased a new position in Aeglea Bio Therapeutics during the first quarter valued at $270,000. Finally, Susquehanna International Group LLP purchased a new position in Aeglea Bio Therapeutics during the second quarter valued at $653,000. Institutional investors and hedge funds own 46.89% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Charles N. York II Purchases 25,959 Shares of Aeglea Bio Therapeutics Inc (AGLE) Stock” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thelincolnianonline.com/2017/12/07/charles-n-york-ii-purchases-25959-shares-of-aeglea-bio-therapeutics-inc-agle-stock.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.